Mike-Andrew Westhoff

Scopus Author ID Loop profile Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 17

Top Topics

Cell Cycle Arrest

Histone Deacetylase

Extracellular Matrix

Top Venues

Pharmaceuticals (Basel, Switzerland)

Inquiry : a journal of medical care organization, provision and financing

This page only lists publications with an associated author ORCID identifier.

Publications

Erika Ongemach, Daniela Zerrinius, Philipp Heimann, Christian Rainer Wirtz, Klaus-Michael Debatin, Mike-Andrew Westhoff, Aurelia Peraud
The Potential Role of the Extracellular Matrix Glycoprotein Reelin in Glioblastoma Biology. Pharmaceuticals (Basel, Switzerland) 17 (3) (2024)
Erika Ongemach, Daniela Zerrinius, Philipp Heimann, Christian Rainer Wirtz, Klaus-Michael Debatin, Mike-Andrew Westhoff, Aurelia Peraud
The Potential Role of the Extracellular Matrix Glycoprotein Reelin in Glioblastoma Biology. Pharmaceuticals (Basel, Switzerland) 17 (3) (2024)
Erika Ongemach, Daniela Zerrinius, Philipp Heimann, Christian Rainer Wirtz, Klaus-Michael Debatin, Mike-Andrew Westhoff, Aurelia Peraud
The Potential Role of the Extracellular Matrix Glycoprotein Reelin in Glioblastoma Biology. Pharmaceuticals (Basel, Switzerland) 17 (3) (2024)
Mike-Andrew Westhoff, Carsten Posovszky, Klaus-Michael Debatin
How to Respond to Misinformation From the Anti-Vaccine Movement. Inquiry : a journal of medical care organization, provision and financing 60 (2023)
Mike-Andrew Westhoff, Carsten Posovszky, Klaus-Michael Debatin
How to Respond to Misinformation From the Anti-Vaccine Movement. Inquiry : a journal of medical care organization, provision and financing 60 (2023)
Mike-Andrew Westhoff, Carsten Posovszky, Klaus-Michael Debatin
How to Respond to Misinformation From the Anti-Vaccine Movement. Inquiry : a journal of medical care organization, provision and financing 60 (2023)
Trang Thi Thu Nguyen, Enyuan Shang, Mike-Andrew Westhoff, Georg Karpel-Massler, Markus D Siegelin
Therapeutic Drug-Induced Metabolic Reprogramming in Glioblastoma. Cells 11 (19) (2022)
Mike-Andrew Westhoff, Marie Schuler-Ortoli, Daniela Zerrinius, Amina Hadzalic, Andrea Schuster, Hannah Strobel, Angelika Scheuerle, Tiana Wong, Christian Rainer Wirtz, Klaus-Michael Debatin, Aurelia Peraud
Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy. Pharmaceuticals (Basel, Switzerland) 15 (1) (2022)
Trang Thi Thu Nguyen, Enyuan Shang, Salveena Schiffgens, Consuelo Torrini, Chang Shu, Hasan Orhan Akman, Varun V Prabhu, Joshua E Allen, Mike-Andrew Westhoff, Georg Karpel-Massler, Markus D Siegelin
Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (9) (2022)
Matthias Schneider, Anna-Laura Potthoff, Bernd O Evert, Marius Dicks, Denise Ehrentraut, Andreas Dolf, Elena N C Schmidt, Niklas Schäfer, Valeri Borger, Torsten Pietsch, Mike-Andrew Westhoff, Erdem Güresir, Andreas Waha, Hartmut Vatter, Dieter Henrik Heiland, Patrick Schuss, Ulrich Herrlinger
Inhibition of Intercellular Cytosolic Traffic via Gap Junctions Reinforces Lomustine-Induced Toxicity in Glioblastoma Independent of MGMT Promoter Methylation Status. Pharmaceuticals (Basel, Switzerland) 14 (3) (2021)
Carolin Golla, Mayas Bilal, Annika Dwucet, Nicolas Bader, Jenson Anthonymuthu, Tim Heiland, Maximilian Pruss, Mike-Andrew Westhoff, Markus David Siegelin, Felix Capanni, Christian Rainer Wirtz, Richard Eric Kast, Marc-Eric Halatsch, Georg Karpel-Massler
Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma. Cancers 13 (16) (2021)
Verena J Herbener, Timo Burster, Alicia Goreth, Maximilian Pruss, Hélène von Bandemer, Tim Baisch, Rahel Fitzel, Markus D Siegelin, Georg Karpel-Massler, Klaus-Michael Debatin, Mike-Andrew Westhoff, Hannah Strobel
Considering the Experimental use of Temozolomide in Glioblastoma Research. Biomedicines 8 (6) (2020)
Trang Thi Thu Nguyen, Yiru Zhang, Enyuan Shang, Chang Shu, Catarina M Quinzii, Mike-Andrew Westhoff, Georg Karpel-Massler, Markus D Siegelin
Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems. Cells 9 (7) (2020)
Enyuan Shang, Trang Thi Thu Nguyen, Chang Shu, Mike-Andrew Westhoff, Georg Karpel-Massler, Markus D Siegelin
Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma. Cancers 12 (8) (2020)
Hannah Strobel, Tim Baisch, Rahel Fitzel, Katharina Schilberg, Markus D Siegelin, Georg Karpel-Massler, Klaus-Michael Debatin, Mike-Andrew Westhoff
Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. Biomedicines 7 (3) (2019)
Anna-Laura Potthoff, Dieter Henrik Heiland, Bernd O Evert, Filipe Rodrigues Almeida, Simon P Behringer, Andreas Dolf, Ági Güresir, Erdem Güresir, Kevin Joseph, Torsten Pietsch, Patrick Schuss, Ulrich Herrlinger, Mike-Andrew Westhoff, Hartmut Vatter, Andreas Waha, Matthias Schneider
Inhibition of Gap Junctions Sensitizes Primary Glioblastoma Cells for Temozolomide. Cancers 11 (6) (2019)
Melanie Mettang, Viola Meyer-Pannwitt, Georg Karpel-Massler, Shaoxia Zhou, Neil O Carragher, Karl Josef Föhr, Bernd Baumann, Lisa Nonnenmacher, Stefanie Enzenmüller, Meike Dahlhaus, Markus D Siegelin, Sebastien Stroh, Daniel Mertens, Pamela Fischer-Posovszky, E Marion Schneider, Marc-Eric Halatsch, Klaus-Michael Debatin, Mike-Andrew Westhoff
Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach. Scientific reports 8 (1) (2018)